ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1537

Qualitative and Quantitative Dosage of the Anti M-Type Phospholipase A2 Receptor Autoantibody: One-Year Experience in Quebec's Reference Center

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Leclerc, Simon, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Benkirane, Karim, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Lamarche, Caroline, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Lafrance, Jean-Philippe, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Nadeau-Fredette, Annie-Claire, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Royal, Virginie, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Pichette, Vincent, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Laurin, Louis-Philippe, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Dosage of the M-type phospholipase A2 receptor antibodies (anti-PLA2R) is now an essential tool for diagnosis and management of primary membranous nephropathy (MN). Since October 2018, Hôpital Maisonneuve-Rosemont (HMR) has been designated as Quebec’s reference center for serum anti-PLA2R antibody testing by the Institut National d’Excellence en Santé et Services Sociaux (INESSS), the regulatory body on drugs and tests usage in Quebec.


All patients who had a serum anti-PLA2R antibody testing performed at HMR from October 1st, 2018 to October 1st, 2019 were included in the study. Serum anti-PLA2R antibodies were screened by a qualitative test, followed by a quantitative test if the results were undetermined or positive. We calculated sensitivity, specificity, predictive value, and likelihood ratio for both tests, using kidney biopsy findings as the gold standard.


In the province of Quebec, a total of 1690 tests were performed among 1025 patients during the study year. A small proportion of these patients (8%) were followed at HMR. Patients tested at HMR and in the rest of Quebec had similar characteristics. Test validity was only characterized for patients tested at HMR. Sensitivity and specificity were, respectively, 58% and 100% for the qualitative test, and 71% and 100% for the quantitative test. The combined net sensitivity was 42% and the net specificity, 100%. The net positive and negative predictive value were 100% and 84% respectively, whereas the net negative likelihood ratio was 0.58.


Serum anti-PLA2R antibody testing was widely used in Quebec during its first year of availability. In one of the biggest real life cohort described, the test performed as previously described in the literatur. Moreover, the two-step approach that was used at HMR, using a qualitative test before a quantitative test if needed, appears to be an efficient way to avoid quantitative testing in negative patients and to better characterize undetermined results on immunofluorescence.


  • Government Support – Non-U.S.